January 13, 2022 07:02 AM EST

CRO owner pleads guilty to obstructing FDA investigation into falsified clinical trial data

Zachary Brennan

Senior Editor

The co-owner of a Florida-based clinical research site pleaded guilty to lying to an FDA investigator during a 2017 inspection, revealing that she falsely portrayed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

CRO owner pleads guilty to obstructing FDA investigation into falsified clinical trial data

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

CRO own­er pleads guilty to ob­struct­ing FDA in­ves­ti­ga­tion in­to fal­si­fied clin­i­cal tri­al da­ta

Senior Editor

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

CRO owner pleads guilty to obstructing FDA investigation into falsified clinical trial data